The company's KardiaMobile and KardiaMobile 6L devices, along with the Kardia app, allow users to take a 30-second ECG and receive instant determinations of multiple cardiac conditions, including atrial fibrillation (AFib), bradycardia, and tachycardia. The latest FDA clearance, under the agency’s "software as a medical device" designation, is for an algorithm suite upgrade that generates enough detail and fidelity that, says the company, positions it to deliver AI-based remote cardiological services for the vast majority of cases when cardiac patients are not in front of their doctor.
"Kardia AI V2 is the most sophisticated AI ever brought to personal ECG," says AliveCor CEO Priya Abani. "This suite of algorithms and visualizations will provide the platform for delivery of new consumer and professional service offerings beyond AFib, by allowing a much wider range of cardiac conditions to be determined on a personal ECG device."
The new FDA 510(K) clearance, says the company, provides detail and fidelity unlike any previously seen in personal ECG devices including:
- A "Sinus Rhythm with Premature Ventricular Contractions (PVCs)" determination if two or more ventricular ectopic beats are detected. PVCs are a common occurrence where extra heart beats originate in the bottom chamber of the heart and occur sooner than the next expected regular heartbeat. After the PVC beat, a pause usually occurs, which causes the next normal heartbeat to be more forceful. When one feels the heart "skip a beat," it is this more forceful beat that is felt.
- A "Sinus Rhythm with Supraventricular Ectopy (SVE)" determination if narrow-complex ectopy, such as premature atrial contractions (PACs), are detected. PACs are similar to PVCs, but these beats originate in the top chamber of the heart, however not in the heart's natural pacemaker, the Sinus Node.
- A "Sinus Rhythm with Wide QRS," determination for QRS intervals of 120ms or longer. Wide QRS indicates that the activation of the bottom chamber of the heart is taking longer